PBPK modeling supports approval of breakthrough cancer drug Video

Pharmacyclics’ (now AbbVie) Imbruvica (ibrutinib) is an anticancer drug targeting B-cell malignancies. Leveraging the US FDA’s accelerated approval programs, the company generated PBPK models using the Simcyp Simulator to inform dose, dosing regimens, and DDIs. Approved initially for mantle cell...

Simcyp PBPK Page

Simcyp® PBPK Modeling & Simulation software helps predict drug behavior, optimize dosing, and guide decisions for safer, more effective treatments.

Clinical Pharmacology Study Execution Team Page

Optimize your clinical trials with Certara's Phase 1 Clinical Pharmacology Services. Comprehensive study design, execution, and regulatory support to ensure success.

Certara Opens New China Office in Shanghai Press Release

Office will support rapid growth and collaboration with customers in China to accelerate biopharmaceutical R&D  PRINCETON, N.J.—Nov. 9, 2020. Certara, a global leader in biosimulation, today announced the opening of a new office in Shanghai’s Pudong District, China’s epicenter for biopharmaceutical research...

How PBPK Modeling Can Replace Drug-Drug Interaction Studies Press Coverage

Patients often take more than one drug at a time, especially elderly patients and those with complex diseases, such as cancer and neurological disorders. Therefore, it is crucial to determine what the potential risk might be of a new drug...